Morgan Stanley Analysts Trim Arrowhead Pharmaceuticals Price Target as Market Expectations Shift
Investment analysts at Morgan Stanley have officially adjusted their financial outlook for Arrowhead Pharmaceuticals by lowering the firm’s price target. The revision
by 
Josh Weiner
Josh Weiner